- Home
- DTF vs ASRT Comparison
DTF vs ASRT Comparison
Compare DTF & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | ASRT |
|---|---|---|
| Founded | 1991 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 69.2M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | DTF | ASRT |
|---|---|---|
| Price | $11.34 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 21.1K | ★ 754.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.10 |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $10.29 | $0.51 |
| 52 Week High | $11.19 | $1.04 |
Technical Indicators
Market Signals| Indicator | DTF | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 52.11 |
| Support Level | $11.27 | $0.65 |
| Resistance Level | $11.35 | $0.79 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.12 | 72.73 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.